Initial Findings from a High Genetic Risk Prostate Cancer Clinic.
Adult
Aged
BRCA1 Protein
/ genetics
BRCA2 Protein
/ genetics
Biopsy
Checkpoint Kinase 2
/ genetics
Colorectal Neoplasms, Hereditary Nonpolyposis
/ genetics
Digital Rectal Examination
Early Detection of Cancer
Genetic Predisposition to Disease
Genetic Testing
Germ-Line Mutation
Humans
Life Style
Male
Medical History Taking
Middle Aged
Nutrition Surveys
Prostate
/ pathology
Prostate-Specific Antigen
/ blood
Prostatic Neoplasms
/ diagnosis
Risk Factors
Urinalysis
Journal
Urology
ISSN: 1527-9995
Titre abrégé: Urology
Pays: United States
ID NLM: 0366151
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
05
02
2021
revised:
06
05
2021
accepted:
11
05
2021
pubmed:
20
7
2021
medline:
1
2
2022
entrez:
19
7
2021
Statut:
ppublish
Résumé
To improve prostate cancer screening for high-risk men, we developed an early detection clinic for patients at high genetic risk of developing prostate cancer. Despite the rapidly growing understanding of germline variants in driving aggressive prostate cancer and the increased availability of genetic testing, there is little evidence surrounding how best to screen these men. We are reporting on the first 45 patients enrolled, men between the ages of 35-75, primarily with known pathogenic germline variants in prostate cancer susceptibility genes. Screening consists of an intake lifestyle survey, PSA, DRE, and SelectMDx urine assay. A biopsy was recommended for any of the following indications: 1) abnormal DRE, 2) PSA above threshold, or 3) SelectMDx above threshold. The primary outcomes were number needed to screen, and number needed to biopsy to diagnose a patient with prostate cancer. Patients enrolled in the clinic included those with BRCA1 (n=7), BRCA2 (n=16), Lynch Syndrome (n=6), and CHEK2 (n = 4) known pathogenic germline variants. The median age and PSA were 58 (range 35-71) and 1.4 ng/ml (range 0.1-11.4 ng/ml), respectively. 12 patients underwent a prostate needle biopsy and there were 4positive biopsies for prostate cancer. These early data support the feasibility of opening a dedicated clinic for men at high genetic risk of prostate cancer. This early report on the initial enrollment of our long-term study will help optimize early detection protocols and provide evidence for personalized prostate cancer screening in men with key pathogenic germline variants.
Identifiants
pubmed: 34280438
pii: S0090-4295(21)00647-6
doi: 10.1016/j.urology.2021.05.078
pii:
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
BRCA2 Protein
0
BRCA2 protein, human
0
Checkpoint Kinase 2
EC 2.7.1.11
CHEK2 protein, human
EC 2.7.11.1
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
96-103Commentaires et corrections
Type : CommentIn
Informations de copyright
Published by Elsevier Inc.